Literature DB >> 31550201

Underutilization of medications to treat opioid use disorder: What role does stigma play?

Bennett Allen1, Michelle L Nolan2, Denise Paone2.   

Abstract

There is consensus in the scientific literature that the opioid agonist medications methadone and buprenorphine are the most effective treatments for opioid use disorder. Despite increasing opioid overdose deaths in the United States, these medications remain substantially underutilized. For no other medical conditions for which an effective treatment exists is that treatment used so infrequently. In this commentary, we discuss the potential role of stigma in the underutilization of these opioid agonist medications for addiction treatment. We outline stigma toward medications for addiction treatment and suggest that structural and policy barriers to methadone and buprenorphine may contribute to this stigma. We offer pragmatic public health solutions to reduce stigma and expand access to these effective treatments.

Entities:  

Keywords:  Opioid use disorder; buprenorphine; health policy; methadone; stigma

Year:  2019        PMID: 31550201     DOI: 10.1080/08897077.2019.1640833

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  17 in total

1.  Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.

Authors:  Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Emily Scherer; Lisa A Marsch
Journal:  J Subst Abuse Treat       Date:  2020-01-21

2.  Health Professional Stigma as a Barrier to Contingency Management Implementation in Opioid Treatment Programs.

Authors:  Kelli Scott; Cara M Murphy; Kimberly Yap; Samantha Moul; Linda Hurley; Sara J Becker
Journal:  Transl Issues Psychol Sci       Date:  2020-10-15

3.  "You're Not Supposed to be on it Forever": Medications to Treat Opioid Use Disorder (MOUD) Related Stigma Among Drug Treatment Providers and People who Use Opioids.

Authors:  Julia Dickson-Gomez; Antoinette Spector; Margaret Weeks; Carol Galletly; Madelyn McDonald; Helena Danielle Green Montaque
Journal:  Subst Abuse       Date:  2022-06-27

4.  A bifurcated opioid treatment system and widening insidious disparities.

Authors:  Erick G Guerrero; Hortensia Amaro; Tenie Khachikian; Mona Zahir; Jeanne C Marsh
Journal:  Addict Behav       Date:  2022-03-02       Impact factor: 4.591

5.  Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.

Authors:  Jennifer Miles; Jason Howell; Dave Sheridan; George Braucht; Amy Mericle
Journal:  Am J Drug Alcohol Abuse       Date:  2020-02-24       Impact factor: 3.829

6.  Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.

Authors:  Paxton Bach; Misha Bawa; Cameron Grant; M J Milloy; Kanna Hayashi
Journal:  Int J Drug Policy       Date:  2021-12-05

7.  Feasibility and acceptability of a digital health intervention to promote engagement in and adherence to medication for opioid use disorder.

Authors:  Kirsten J Langdon; Caroline Scherzer; Susan Ramsey; Kate Carey; Josiah Rich; Megan L Ranney
Journal:  J Subst Abuse Treat       Date:  2021-06-16

8.  It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver.

Authors:  Brendan Saloner; Barbara Andraka Christou; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2021-04-02       Impact factor: 3.716

9.  Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.

Authors:  Mara A G Hollander; Chung-Chou H Chang; Antoine B Douaihy; Eric Hulsey; Julie M Donohue
Journal:  Drug Alcohol Depend       Date:  2021-07-28       Impact factor: 4.852

10.  Interventions for hospitalized medical and surgical patients with opioid use disorder: A systematic review.

Authors:  Rachel French; Shoshana V Aronowitz; J Margo Brooks Carthon; Heath D Schmidt; Peggy Compton
Journal:  Subst Abus       Date:  2021-07-20       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.